Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatment.

doi:10.1016/j.jcv.2018.04.001

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatment.

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology - 1 Jul 2018

Armenia Daniele, Zaccarelli Mauro, Borghi Vanni, Gennari William, Di Carlo Domenico, Giannetti Alberto, Forbici Federica, Bertoli Ada, Gori Caterina, Fabeni Lavinia, Pinnetti Carmela, Marocco Raffaella, Latini Alessandra, Ceccherini-Silberstein Francesca, Mastroianni Claudio Maria, Mussini Cristina, Antinori Andrea, Perno Carlo Federico, Santoro Maria Mercedes

Abstract excerpt

BACKGROUND: Genotypic resistance test (GRT) performed in peripheral blood mononuclear cells (PBMC) represents a chance to evaluate resistance in virologically suppressed HIV infected patients. OBJECTIVES: To evaluate the impact of baseline resistance detected through PBMC GRT on virological rebound after switching treatment. STUDY DESIGN: Baseline genotypic susceptibility scores (GSS) from PBMC GRT (DNA-GSS) and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA, Viral

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Genotype

Share to HIV-1

Share to HIV Infections

Share to Leukocytes, Mononuclear

Share to Microbial Sensitivity Tests

Share to Prognosis

Share to Proviruses

Source

Open in PubMed

Identifiers

PMID: 29738896
DOI: 10.1016/j.jcv.2018.04.001

Genes

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatment.PMID 29738896Read ↗

Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA.Semantic proximity Read ↗

Effect of suppressing HIV viremia on the HIV progression of patients undergoing a genotype resistance test after treatment failure.Semantic proximity Read ↗

Genotypic susceptibility score (GSS) and CD4+ T cell recovery in HIV-1 patients with suppressed viral load.Semantic proximity Read ↗

HIV drug resistance detected during low-level viraemia is associated with subsequent virologic failure.Semantic proximity Read ↗

Temporal trend of drug-resistance and APOBEC editing in PBMC genotypic resistance tests from HIV-1 infected virologically suppressed individuals.Semantic proximity Read ↗

Efficacy of raltegravir switching strategies in HIV-infected patients with suppressed viraemia according to the genotypic sensitivity score.Semantic proximity Read ↗

High virological suppression regardless of the genotypic susceptibility score after switching to a dolutegravir-based regimen: week 48 results in an observational cohort.Semantic proximity Read ↗

Drug-resistance mutations number and K70R or T215Y/F substitutions predict treatment resumption during guided treatment interruptions.Semantic proximity Read ↗

Evolution of HIV-1 genotype in plasma RNA and peripheral blood mononuclear cells proviral DNA after interruption and resumption of antiretroviral therapy.Semantic proximity Read ↗

Viral suppression following switch to second-line antiretroviral therapy: associations with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switch.Semantic proximity Read ↗

Cellular HIV-1 DNA levels in drug sensitive strains are equivalent to those in drug resistant strains in newly-diagnosed patients in Europe.Semantic proximity Read ↗

Switching to bictegravir/emtricitabine/tenofovir alafenamide in people with HIV and prior resistance mutations. Data from the Italian ARCA cohort: the BIC-BARRIER study. B/F/TAF switch: mutations and outcomes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.